Pharmacological PLAG1 inhibition demonstrated synergistic effects with sorafenib across preclinical HCC models, though functional characterization of the PVT1/miR-195-5p/PLAG1 axis in ferroptosis modulation remains incomplete due to observed phenotypic heterogeneity [63]. This evidence concerns the gene PLAG1 and hepatocellular carcinoma.